一纸国家药品监督管理局核准批文，宣告万邦德（002082）通过引进创新型药剂，成功进入ED治疗领 域。 总部位于浙江湖州的万邦德，聚焦医药制造和医疗器械大健康产业，主营业务集医药制造和医疗器械研 发、生产、销售于一体。今年前三季度，公司营业总收入10.18亿元，净利润为446.78万元。 11月26日晚，万邦德公告称，万邦德全资子公司万邦德制药集团浙江医药（600216）销售有限公司(下 称"万邦德销售公司")获得西班牙Farmalider,S.A.(以下简称"Farmalider")的枸橼酸西地那非口服混悬液(下 称"西地那非口服混悬液")在中国大陆市场10年的独家进口权和独家销售权，近日收到Farmalider授权方 NULIFE GROUPE LIMITED礼易集团有限公司(下称"礼易集团")的通知，获悉西地那非口服混悬液已取 得国家药品监督管理局核准签发的《药品注册证书》。 对于此次批文的影响，万邦德表示，西地那非口服混悬液取得《药品注册证书》，标志着公司未来10年 可独家进行该产品在中国大陆市场的进口和销售。公司通过引进创新型剂型进入ED领域，能够更好满 足不同群体的用药需求。 据悉，枸橼酸西地那非 ...

每经AI快讯，11月26日，万邦德公告，公司全资子公司万邦德制药集团浙江医药销售有限公司收到国 家药品监督管理局签发的枸橼酸西地那非口服混悬液《药品注册证书》。该产品用于治疗男性勃起功能 障碍（ED）。 ...

Group 1: Storage Market Dynamics - The storage spot market is experiencing strong demand, leading to continued price increases for finished products, despite high prices [1] - Customers with low inventory levels are gradually accepting new pricing agreements, providing manufacturers with confidence to raise prices [1] - The significant price increases are affecting retail markets, with online and offline retailers raising prices for memory modules and SSDs, potentially reducing consumer purchasing willingness [1] Group 2: DRAM Industry Forecast - According to TrendForce, the DRAM industry revenue is expected to grow by 30.9% quarter-on-quarter in Q3 2025, reaching $41.4 billion due to rising contract prices and increased shipment volumes [1] - The fourth quarter is anticipated to see a significant increase in contract prices, with conventional DRAM prices expected to rise by 45%-50% [1] - The overall contract prices for conventional DRAM and HBM combined are projected to increase by 50%-55% [1] Group 3: Medical Device Market Growth - The Chinese medical device market is projected to reach ¥1.22 trillion by 2025, with over 33,000 production enterprises expected by the end of 2024, marking a 27.8% increase from the end of the 13th Five-Year Plan [2] - The industry is transitioning from "catching up" to "running alongside and leading," supporting the "Healthy China" strategy [2] Group 4: Flu Season Impact on Pharmaceuticals - The flu season has started early in China, with a 237% increase in sales of Oseltamivir over the past week, and a 180% increase for Maviral [2] - The peak of the flu season is expected between mid-December and early January [2] Group 5: Cinema Industry Growth - As of October 2023, China has added 233 cinemas and 1,588 screens, totaling 15,438 operating cinemas and 92,556 screens nationwide [3] - County-level cinemas account for 21.06% of the total, while town cinemas make up 18.01% [3] Group 6: Innovations in Medical Technology - Novo Nordisk's Kyinsu, the world's first weekly insulin and GLP-1 receptor agonist combination, has been approved in the EU for adults with type 2 diabetes [3] - This innovation represents a significant advancement in diabetes treatment options [3] Group 7: Corporate Developments - Allianz Partners plans to lay off 1,500 to 1,800 employees over the next 12-18 months, primarily in call center roles due to automation [5] - Novartis announced plans to cut up to 550 jobs in Switzerland by the end of 2027 as part of production adjustments [5]

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

Core Viewpoint - Wanbangde Pharmaceutical has obtained exclusive import and sales rights for Sildenafil Citrate Oral Suspension in mainland China for 10 years, marking a significant opportunity in the erectile dysfunction (ED) treatment market [1] Group 1: Company Developments - Wanbangde's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Zhejiang Medical Sales Co., Ltd., has secured exclusive rights from Farmalider, S.A. for the product in China [1] - The product has received the Drug Registration Certificate from the National Medical Products Administration, allowing for its import and sale [1] Group 2: Product Information - Sildenafil Citrate Oral Suspension is a selective inhibitor of phosphodiesterase type 5 (PDE5), specifically targeting cyclic guanosine monophosphate (cGMP) [1] - The product is clinically used for treating male erectile dysfunction, indicating its relevance in addressing a significant health issue [1] Group 3: Market Implications - The exclusive rights for the next decade enable the company to better meet the medication needs of different patient groups in the ED market [1]

证券代码：002082 证券简称：万邦德 公告编号：2025-065 万邦德医药控股集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团浙江医药销售有限公司（以下简称"万邦德销售公司"）获得西班牙 Farmalider, S.A.（以下简称"Farmalider"）的枸橼酸西地那非口服混悬液(以 下简称"西地那非口服混悬液"）在中国大陆市场 10 年的独家进口权和独家销 售权，近日收到 Farmalider 授权方 NULIFE GROUPE LIMITED 礼易集团有限公司 （以下简称"礼易集团"）的通知，获悉西地那非口服混悬液已取得国家药品监 督管理局核准签发的《药品注册证书》。现将有关事宜公告如下： 英文名/拉丁名：Sildenafil Citrate Oral Suspension 剂型：口服混悬剂 关于子公司独家代理进口产品取得药品注册证书的公告 申请事项：药品注册(境外生产) 注册分类：化学药品 5.1 类 规格：30ml:0.75g（按 C₂₂H₃₀N₆O₄ ...

万邦德公告，全资子公司万邦德制药集团浙江医药销售有限公司获得西班牙Farmalider,S.A.的枸橼酸西 地那非口服混悬液在中国大陆市场10年的独家进口权和独家销售权。近日，万邦德销售公司收到授权方 礼易集团的通知，获悉西地那非口服混悬液已取得国家药品监督管理局核准签发的《药品注册证书》。 枸橼酸西地那非口服混悬液是一种对环磷酸鸟苷特异的5型磷酸二酯酶选择性抑制剂，临床用于治疗男 性勃起功能障碍。 ...

Core Viewpoint - The company is advancing the development of WP103, an innovative drug targeting Hypoxic-Ischemic Encephalopathy (HIE) in newborns, which currently has no approved treatments globally [1] Group 1: Disease Significance and Market Potential - HIE is a serious neonatal brain injury caused by lack of oxygen and reduced blood flow, leading to high mortality rates and long-term neurological issues such as cerebral palsy and epilepsy, imposing a heavy burden on families and society [1] - The market for HIE treatments is vast, with hundreds of thousands of infants affected annually, and the market capacity is expected to reach $10 billion [1] Group 2: Drug Development Progress - WP103 has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA, indicating its innovative value and potential for 7 years of market exclusivity, priority review for new drug applications, and exemption from registration fees [1] - Recent large animal efficacy studies have shown WP103's promising therapeutic effects on key indicators, improving behavioral, neurological scores, and brain tissue pathology [1] - The company plans to communicate with the FDA to advance clinical research for HIE following the completion of preclinical studies [1] Group 3: Company Strategy and Expertise - The company has focused on HIE as a breakthrough area due to the lack of available treatments and urgent clinical needs, supported by a dedicated R&D team of approximately 120 members [1] - The company has established high-end platforms, including a postdoctoral workstation and an academician workstation, and has closely collaborated with the FDA to design non-clinical studies, which has been crucial for the rapid advancement of the project [1]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced significant fluctuations, with a year-to-date increase of 107.62% but a recent decline of 9.25% over the last five trading days [1] - As of November 19, Wanbangde's stock price was reported at 13.35 yuan per share, with a total market capitalization of 8.166 billion yuan [1] - The company has seen a net inflow of main funds amounting to 503,000 yuan, with large orders showing a mixed buying and selling trend [1] Group 2 - Wanbangde Medical Holdings Group Co., Ltd. was established on March 31, 1999, and listed on November 20, 2006, with its main business involving the production and sales of aluminum processing products and medical devices [2] - The revenue composition of Wanbangde includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] - As of September 30, the number of shareholders decreased by 32.75% to 26,400, while the average circulating shares per person increased by 48.70% to 20,944 shares [2] Group 3 - Wanbangde has distributed a total of 613 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002082 证券简称：万邦德 公告编号：2025-063 万邦德医药控股集团股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议召开时间： 1）现场会议时间：2025年11月17日下午14:00。 2）网络投票时间：通过深圳证券交易所交易系统进行投票的具体时间为2025年11月17日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网系统进行投票的具体时间为2025年11月17日9:15至 15:00的任意时间。 2、会议召开地点：浙江省台州市温岭市城东街道百丈北路28号，公司行政楼会议室。 3、会议召集人：万邦德医药控股集团股份有限公司（以下简称"公司"）董事会 4、会议主持人：董事刘同科先生。 5、会议召开方式：本次会议采取现场投票表决和网络投票表决相结合的方式召开。 会议的召集 ...